Heart failure & cardiomyopathiesSecondary analysis
Effects of finerenone across a range of heart failure duration: a prespecified analysis of the FINEARTS-HF trial
- Prespecified analysis of the FINEARTS-HF randomised trial
Authors' conclusion
These findings suggest that even patients with long-standing HF with only mild functional status limitation may still benefit from further therapeutic optimization with therapies such as finerenone.
Study context
- Population
- Patients with heart failure (HF) in FINEARTS-HF, by HF duration from diagnosis (<3 months, ≥3 months to 2 years, ≥2 to 5 years, ≥5 years)with available data
- Participants
- 5,977 patients
- Comparison
- Finerenone vs placebo across HF duration categories
- Primary endpoint
- Composite of:
- CV death
- Total HF events
Primary result
As reported in the abstract
Primary outcome by HF duration
Finerenone vs PlaceboRate ratio (95% CI)
HF duration <3 months
0.84(0.61–1.16)
HF duration ≥3 months to 2 years
0.95(0.74–1.23)
HF duration ≥2 to 5 years
0.77(0.61–0.98)
HF duration ≥5 years
0.81(0.64–1.02)
Further findings
Primary outcome risk by HF duration (vs <3 months)
- Longer HF duration: significantly higher adjusted risk of the primary outcome
Safety
Drug discontinuation due to serious adverse events
- Similar between finerenone and placebo, regardless of HF duration
Original publication
Effects of finerenone across a range of heart failure duration: a prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. Published 8 April 2026. doi:10.1093/ejhf/xuag119
Summarised from the published abstract; every number is checked against it